Blueprint Medicines Corporation
BPMC
Peringkat dalam Saham
#2365
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Harga Saham
$129.46
Terakhir disinkronkan: 2025-07-18
Kapitalisasi Pasar
$8.36B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Blueprint Medicines Corporation (BPMC)
Kategori
Healthcare
Rasio P/E untuk Blueprint Medicines Corporation (BPMC)
Rasio P/E per October 2026 TTM: -120.99
Menurut laporan keuangan dan harga saham terbaru dari Blueprint Medicines Corporation, rasio P/E saat ini (TTM) adalah -120.99. Pada akhir 2023, perusahaan memiliki rasio P/E sebesar -11.02.
Riwayat rasio P/E untuk Blueprint Medicines Corporation dari 2013 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | -120.99 | 48.06% |
| 2024 | -81.72 | 641.69% |
| 2023 | -11.02 | 135.09% |
| 2022 | -4.69 | -51.84% |
| 2021 | -9.73 | -149.94% |
| 2020 | 19.49 | -267.16% |
| 2019 | -11.66 | 16.64% |
| 2018 | -9.99 | -48.06% |
| 2017 | -19.24 | 80.88% |
| 2016 | -10.64 | 16.86% |
| 2015 | -9.10 | 48.53% |
| 2014 | -6.13 | -48.09% |
| 2013 | -11.81 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 28.78 | -123.79% |
US
|
|
| -28.36 | -76.56% |
US
|
|
| -24.57 | -79.70% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -125.07% |
NL
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.